Oxford BioMedicas gene therapy ProSavin effective in parkinsons

Oxford BioMedica  have announced promising results from the Phase I/II trial of its gene therapy, ProSavin, for the treatment of Parkinson’s disease. It delivers three genes required to convert cells that normally do not produce dopamine into cells that do.